Orgenesis Inc. (NASDAQ:ORGS – Get Free Report) saw a significant growth in short interest in July. As of July 31st, there was short interest totalling 359,900 shares, a growth of 48.4% from the July 15th total of 242,600 shares. Based on an average trading volume of 141,500 shares, the short-interest ratio is currently 2.5 days.
Orgenesis Stock Performance
NASDAQ ORGS traded up $0.12 during trading on Wednesday, hitting $1.02. 747,238 shares of the stock traded hands, compared to its average volume of 185,166. Orgenesis has a 12-month low of $0.25 and a 12-month high of $1.08. The firm has a 50-day simple moving average of $0.64 and a 200-day simple moving average of $0.59.
Orgenesis (NASDAQ:ORGS – Get Free Report) last released its quarterly earnings data on Tuesday, May 21st. The company reported ($0.29) earnings per share (EPS) for the quarter. The business had revenue of $0.14 million for the quarter.
Orgenesis Company Profile
Orgenesis Inc, a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals.
Read More
- Five stocks we like better than Orgenesis
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Brinker International’s Price Dip is an Appetizing Entry Point
- Best Stocks Under $5.00
- 3 Stocks That Could Beat the September Blues
- What is a buyback in stocks? A comprehensive guide for investors
- Canopy Growth Stock: Can It Sustain Recent Gains?
Receive News & Ratings for Orgenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orgenesis and related companies with MarketBeat.com's FREE daily email newsletter.
